BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 26059239)

  • 21. Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway.
    Shi H; Pu J; Zhou XL; Ning YY; Bai C
    Tumour Biol; 2017 May; 39(5):1010428317697568. PubMed ID: 28459375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dickkopf-3 (Dkk3) induces apoptosis in cisplatin-resistant lung adenocarcinoma cells via the Wnt/β-catenin pathway.
    Wang Z; Ma LJ; Kang Y; Li X; Zhang XJ
    Oncol Rep; 2015 Mar; 33(3):1097-106. PubMed ID: 25573172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression.
    Lu KH; Li W; Liu XH; Sun M; Zhang ML; Wu WQ; Xie WP; Hou YY
    BMC Cancer; 2013 Oct; 13():461. PubMed ID: 24098911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. C-Myc participates in β-catenin-mediated drug resistance in A549/DDP lung adenocarcinoma cells.
    Xie C; Pan Y; Hao F; Gao Y; Liu Z; Zhang X; Xie L; Jiang G; Li Q; Wang E
    APMIS; 2014 Dec; 122(12):1251-8. PubMed ID: 25131138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel herbal formula induces cell cycle arrest and apoptosis in association with suppressing the PI3K/AKT pathway in human lung cancer A549 cells.
    Xiong F; Jiang M; Huang Z; Chen M; Chen K; Zhou J; Yin L; Tang Y; Wang M; Ye L; Zhan Z; Duan J; Fu H; Zhang X
    Integr Cancer Ther; 2014 Mar; 13(2):152-60. PubMed ID: 24105357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GLIPR1 modulates the response of cisplatin-resistant human lung cancer cells to cisplatin.
    Gong X; Liu J; Zhang D; Yang D; Min Z; Wen X; Wang G; Li H; Song Y; Bai C; Li J; Zhou J
    PLoS One; 2017; 12(8):e0182410. PubMed ID: 28771580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNA-130b targets PTEN to induce resistance to cisplatin in lung cancer cells by activating Wnt/β-catenin pathway.
    Zhang Q; Zhang B; Sun L; Yan Q; Zhang Y; Zhang Z; Su Y; Wang C
    Cell Biochem Funct; 2018 Jun; 36(4):194-202. PubMed ID: 29653464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1.
    Zhang H; Hu B; Wang Z; Zhang F; Wei H; Li L
    Cancer Chemother Pharmacol; 2017 Nov; 80(5):973-984. PubMed ID: 28956120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long noncoding LUCAT1 promotes cisplatin resistance of non-small cell lung cancer by promoting IGF-2.
    Wang W; Dong ML; Zhang W; Liu T
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5229-5234. PubMed ID: 31298373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NORAD accelerates chemo-resistance of non-small-cell lung cancer via targeting at miR-129-1-3p/SOX4 axis.
    Huang Q; Xing S; Peng A; Yu Z
    Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sox2 inhibits Wnt-β-catenin signaling and metastatic potency of cisplatin-resistant lung adenocarcinoma cells.
    He J; Shi J; Zhang K; Xue J; Li J; Yang J; Chen J; Wei J; Ren H; Liu X
    Mol Med Rep; 2017 Apr; 15(4):1693-1701. PubMed ID: 28259951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of lncRNA-BLACAT1 on drug resistance of non-small cell lung cancer cells in DDP chemotherapy by regulating cyclin D1 expression.
    Ju ZS; Sun B; Bao D; Zhang XF
    Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9465-9472. PubMed ID: 33015788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
    Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hsa_circ_0096157 silencing suppresses autophagy and reduces cisplatin resistance in non-small cell lung cancer by weakening the Nrf2/ARE signaling pathway.
    Lu H; Kong J; Cai S; Huang H; Luo J; Liu L
    Mol Biol Rep; 2024 Jun; 51(1):703. PubMed ID: 38822881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
    Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
    Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GAS5 knockdown reduces the chemo-sensitivity of non-small cell lung cancer (NSCLC) cell to cisplatin (DDP) through regulating miR-21/PTEN axis.
    Cao L; Chen J; Ou B; Liu C; Zou Y; Chen Q
    Biomed Pharmacother; 2017 Sep; 93():570-579. PubMed ID: 28686971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Silence of  lncRNA UCA1 rescues drug resistance of cisplatin to non-small-cell lung cancer cells.
    Liu X; Huang Z; Qian W; Zhang Q; Sun J
    J Cell Biochem; 2019 Jun; 120(6):9243-9249. PubMed ID: 30652341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a.
    Cheng C; Qin Y; Zhi Q; Wang J; Qin C
    Int J Biol Macromol; 2018 Feb; 107(Pt B):2620-2629. PubMed ID: 29080815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells.
    Jiang P; Wu X; Wang X; Huang W; Feng Q
    Oncotarget; 2016 Jul; 7(28):43337-43351. PubMed ID: 27270317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
    Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
    Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.